Martin Schrappe.

Martin Schrappe, M.D., Stephen P. Hunger, M.D., Ching-Hon Pui, M.D., Vaskar Saha, F.R.C.P.C.H., Paul S. Gaynon, M.D.D., Valentino Conter, M.D., Jacques Otten, M.D., Akira Ohara, M.D., Ph.D., Anne Birgitta Versluys, M.D., Gabriele Escherich, M.D., Mats Heyman, M.D., Ph.D., Lewis B. Silverman, M.D., Keizo Horibe, M.D., Ph.D., Georg Mann, M.D., Bruce M. Camitta, M.D., Jochen Harbott, Ph.D.D., Sue Richards, D.Phil., Meenakshi Devidas, Ph.D., and Martin Zimmermann, Ph.D.: Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia Current treatment for severe lymphoblastic leukemia may effect a remedy in approximately 80 percent of children with the disease.1-9 The leading reason behind treatment failure is relapse, for which several risk factors have been identified, with inadequate therapy being one of the most important.10-19 A small but significant %age of patients do not have a complete remission after 4 to 6 6 weeks of induction chemotherapy.20-23 Among patients with preliminary induction failure, some never have a complete remission & most others have early relapse.Related StoriesFlorida Institute finalizes financing contract with Genetic NetworksMoffitt Cancer Center study finds link between common gene mutations and tumor immune surveillanceDisclosing genetic risk for CHD results in lower low-density lipoprotein cholesterol’In my experience working with kids in Ecuador, these parasites, when within large numbers in an individual particularly, can have profound effects on health,’ says Professor Philip Cooper, clinician and author from the Liverpool School of Tropical Medicine. ‘With an increase of than 800 million children worldwide looking for treatment against these specific worms, and because we have just a few drugs that are effective and safe against these parasites, it is essential that people focus our analysis on finding new treatments before resistance to the drugs we have has a opportunity to build up.